4 patient evaluations for Dalfampridine (4-AP extended release) taken for the purpose of 'Multiple Sclerosis' with a side effects rating of Severe

LSK
12214 thumb
LSK
Sex: F
Data Quality: 3 stars
Relapse: Mild
Sensation: Moderate
Overall: Moderate
Cognition: severe
Vision: none
Speech: moderate
Swallowing: mild
Upper limb: moderate
Walking: moderate
I am: g
I have:
MS

See LSK's full Dalfampridine (4-AP extended release) history

Dec 9, 2013 (Started Nov 22, 2013)

  • Perceived effectiveness for Multiple Sclerosis: None
  • Perceived effectiveness for Improve mobility: None
  • Side Effects: Severe
  • Adherence: Always
  • Burden: Somewhat
Dosage: 2 tablet(s) Daily
Cost: $50-99 monthly

  • 0 helpful marks
ukiwi
9816 thumb
ukiwi
Sex: M
Data Quality: 3 stars
Sensation: Moderate
Overall: Mild
Cognition: moderate
Vision: moderate
Speech: none
Swallowing: none
Upper limb: none
Walking: mild
I am: n
I have:
MS

See ukiwi's full Dalfampridine (4-AP extended release) history

Jul 18, 2012 (Started Jul 01, 2012)

  • Perceived effectiveness for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Major
  • Perceived effectiveness for Multiple Sclerosis: Major
  • Side Effects: Severe
  • Adherence: Always
  • Burden: Not at all
Dosage: 1 other Daily

  • 0 helpful marks
Darlingniki469
11129 thumb
Darlingniki469
Sex: F
Data Quality: 1 star
Relapse: Moderate
Sensation: Severe
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: moderate
Swallowing: moderate
Upper limb: moderate
Walking: severe
I am: g
I have:
MS

See Darlingniki469's full Dalfampridine (4-AP extended release) history

Feb 3, 2012 (Started Jul 15, 2010)

  • Perceived effectiveness for Walking problems: None
  • Perceived effectiveness for Improve flexibility/strength: None
  • Perceived effectiveness for Multiple Sclerosis: None
  • Side Effects: Severe
  • Adherence: Usually
  • Burden: Not at all
Dosage: 20 mg Daily
Cost: < $25 monthly

  • 0 helpful marks
ashmo
12315 thumb
ashmo
Sex: F
Data Quality: 1 star
Relapse: Moderate
Sensation: Severe
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: mild
Swallowing: mild
Upper limb: moderate
Walking: severe
I am: b
I have:
MS

See ashmo's full Dalfampridine (4-AP extended release) history

Sep 15, 2011 (Started Mar 01, 2011)

  • Perceived effectiveness for Multiple Sclerosis: None
  • Perceived effectiveness for Walking problems: None
  • Side Effects: Severe
  • Adherence: Usually
  • Burden: Not at all
Advice & Tips: when a flare- up begins, check with your doctor immediately. it may be the Ampyra as it causes flare-ups.
Cost: < $25 monthly

  • 1 helpful mark
Last updated:
Showing 4 of 4 patient evaluations for Dalfampridine (4-AP extended release)